|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...99100101102103104105106107108109110111» |
- Clinical: Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass (clinicaltrials.gov) - Nov 12, 2011
P=N/A, N=800, Recruiting, Sponsor: HaEmek Medical Center, Israel
- Torisel (temsirolimus) / Pfizer
Trial termination: Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse (clinicaltrials.gov) - Nov 8, 2011
P2, N=9, Terminated, Sponsor: Hellenic Cooperative Oncology Group
Recruiting --> Terminated; The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment
- Torisel (temsirolimus) / Pfizer
Enrollment change: Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse (clinicaltrials.gov) - Nov 8, 2011
P2, N=9, Terminated, Sponsor: Hellenic Cooperative Oncology Group
Recruiting --> Terminated; The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment N=38 --> 9
- ||| RG 7600 / Roche
New P1 trial: A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Nov 8, 2011
P1, N=71, Active, not recruiting, Sponsor: Genentech
- Enrollment change: Beta Cell Function in Women With Turner Syndrome (clinicaltrials.gov) - Nov 6, 2011
P=N/A, N=25, Terminated, Sponsor: University of Aarhus
N=38 --> 9 N=12 --> 25
- Trial completion: Growth Hormone Treatment of Women With Turner Syndrome (clinicaltrials.gov) - Nov 6, 2011
P=N/A, N=24, Completed, Sponsor: Britta E. Hjerrild
N=12 --> 25 Recruiting --> Completed
- metformin / Generic mfg.
Enrollment change, Combination therapy: Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Nov 6, 2011
P2, N=114, Completed, Sponsor: Milton S. Hershey Medical Center
Recruiting --> Completed N=150 --> 114
- Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
Trial completion: Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls (clinicaltrials.gov) - Nov 6, 2011
P4, N=5532, Completed, Sponsor: London School of Hygiene and Tropical Medicine
N=150 --> 114 Recruiting --> Completed
- Clinical: Implementation of an Efficacious Intervention for High Risk Women in Mexico (clinicaltrials.gov) - Nov 3, 2011
P=N/A, N=1080, Recruiting, Sponsor: University of California, San Diego
- | thyroxine / Generic mfg.
New P4 trial: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Nov 3, 2011
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Avastin (bevacizumab) / Roche
Trial termination, Metastases: Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor (clinicaltrials.gov) - Nov 2, 2011
P2, N=5, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Active, not recruiting --> Terminated; Slow accrual.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Avastin (bevacizumab) / Roche
Enrollment change, Metastases: Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor (clinicaltrials.gov) - Nov 2, 2011
P2, N=5, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Slow accrual. N=18 --> 5
- Ontak (denileukin diftitox) / Eisai, TSD Japan
Enrollment closed, Metastases: Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine (clinicaltrials.gov) - Nov 2, 2011
P1, N=8, Active, not recruiting, Sponsor: University of Washington
N=18 --> 5 Recruiting --> Active, not recruiting
- Rubraca (rucaparib) / Pharma& Schweiz
Enrollment change, BRCA Biomarker, PARP Biomarker, Metastases: CRUK-PARP/BRCA: Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer (clinicaltrials.gov) - Nov 1, 2011
P2, N=84, Active, not recruiting, Sponsor: Cancer Research UK
Recruiting --> Active, not recruiting N=56 --> 84
- cisplatin / Generic mfg., amifostine / Generic mfg.
Trial completion: Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer (clinicaltrials.gov) - Nov 1, 2011
P1/2, N=45, Completed, Sponsor: Radiation Therapy Oncology Group
N=56 --> 84 Active, not recruiting --> Completed
- Preclinical, Trial suspension: Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization (IVF) (clinicaltrials.gov) - Oct 31, 2011
P2/3, N=250, Suspended, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Recruiting --> Suspended
- Surgery: Electronic Catheter Stethoscope (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=500, Recruiting, Sponsor: University of South Florida
- ||| varlilumab (CDX 1127) / Celldex
Enrollment open: A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers (clinicaltrials.gov) - Oct 27, 2011
P1, N=170, Recruiting, Sponsor: Celldex Therapeutics
Recruiting --> Suspended Not yet recruiting --> Recruiting
- medroxyprogesterone injection / Generic mfg.
New P3 trial, Adverse events: Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects (clinicaltrials.gov) - Oct 26, 2011
P3, N=45, Recruiting, Sponsor: Nationwide Children's Hospital
- |||||||||| carboplatin / Generic mfg., cisplatin / Generic mfg.
New P3 trial, Metastases: Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer (clinicaltrials.gov) - Oct 25, 2011
P3, N=154, Recruiting, Sponsor: Asan Medical Center
- | Torisel (temsirolimus) / Pfizer
New P2 trial, Metastases: Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma (clinicaltrials.gov) - Oct 25, 2011
P2, N=86, Active, not recruiting, Sponsor: AGO Study Group
- ||| Enrollment change: EURAS-IUD: European Active Surveillance Study for Intrauterine Devices (clinicaltrials.gov) - Oct 24, 2011
P4, N=60000, Active, not recruiting, Sponsor: Center for Epidemiology and Health Research, Germany
Not yet recruiting --> Recruiting N=50000 --> 60000
- ||||| carboplatin / Generic mfg., docetaxel / Generic mfg.
New P2 trial, Metastases: Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer (clinicaltrials.gov) - Oct 24, 2011
P2, N=110, Recruiting, Sponsor: Asan Medical Center
- ||| varlilumab (CDX 1127) / Celldex
New P1 trial: A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers (clinicaltrials.gov) - Oct 24, 2011
P1, N=170, Recruiting, Sponsor: Celldex Therapeutics
- Clinical: High Plasma Level of Long Pentraxin 3 is Associated With Insulin Resistance in Women With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Oct 22, 2011
P=N/A, N=80, Completed, Sponsor: Gulhane School of Medicine
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P2 trial: Efficacy and Safety of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Oct 20, 2011
P2, N=487, Completed, Sponsor: Takeda
- || New P3 trial, Metastases: Hyperthermia Combined Brachytherapy in CCU (clinicaltrials.gov) - Oct 19, 2011
P3, N=224, Completed, Sponsor: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
- New P1 trial: Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome (clinicaltrials.gov) - Oct 19, 2011
P1, N=42, Completed, Sponsor: G
- ||||| apitolisib (GDC-0980) / Roche
New P2 trial: A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma (clinicaltrials.gov) - Oct 18, 2011
P2, N=56, Active, not recruiting, Sponsor: Genentech
- lidocaine topical / Generic mfg.
Clinical: Efficacy of a Physiotherapy Treatment in Women Suffering From Provoked Vestibulodynia (clinicaltrials.gov) - Oct 17, 2011
P=N/A, N=234, Recruiting, Sponsor: Université de Sherbrooke
- ||||||| Priligy (dapoxetine) / AbbVie
Trial completion: The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy (clinicaltrials.gov) - Oct 16, 2011
P3, N=285, Completed, Sponsor: Johnson & Johnson Pte Ltd
N=50000 --> 60000 Recruiting --> Completed
- ||| lifastuzumab vedotin (DNIB0600A) / Roche
Enrollment open: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Oct 16, 2011
P1, N=96, Recruiting, Sponsor: Genentech
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P2 trial: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Oct 13, 2011
P2, N=450, Recruiting, Sponsor: Takeda
- ||| Trial completion: Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela (clinicaltrials.gov) - Oct 13, 2011
P=N/A, N=329, Completed, Sponsor: Instituto Oncologico Luis Razetti
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- Cetrotide (cetrorelix) / EMD Serono
Trial completion: The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors (clinicaltrials.gov) - Oct 12, 2011
P=N/A, N=20, Completed, Sponsor: Virginia Center for Reproductive Medicine
Not yet recruiting --> Completed Enrolling by invitation --> Completed
- | cisplatin / Generic mfg.
Trial completion: CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy (clinicaltrials.gov) - Oct 12, 2011
P3, N=601, Completed, Sponsor: International Atomic Energy Agency
Enrolling by invitation --> Completed Not yet recruiting --> Completed
- Enrollment closed: SHAPE: Sexual Health on Antidepressants Through Physical Exercise (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=75, Active, not recruiting, Sponsor: University of Texas at Austin
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=474, Completed, Sponsor: Taipei Medical University WanFang Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial completion: Obesity and Clinical Presentation of Hyperandrogenism (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=46, Completed, Sponsor: Taipei Medical University WanFang Hospital
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Expression of CVD and HA Between Obesity and Non-obesity Polycystic Ovary Syndrome (PCOS) Women in Taiwan (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=627, Completed, Sponsor: Taipei Medical University WanFang Hospital
Recruiting --> Completed Recruiting --> Completed
- | carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion: Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer (clinicaltrials.gov) - Oct 10, 2011
P2, N=40, Completed, Sponsor: Southeastern Gynecologic Oncology
Recruiting --> Completed Recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg.
Trial completion: DOXIL for Consolidation Therapy in Ovarian Cancer. (clinicaltrials.gov) - Oct 10, 2011
P2, N=45, Completed, Sponsor: Southeastern Gynecologic Oncology
Recruiting --> Completed Recruiting --> Completed
- Trial completion: PCOSLFEA: Acupuncture and Gonadotropin-releasing Hormone Pulse Generator and Stress Axis in Polycystic Ovary Syndrome (clinicaltrials.gov) - Oct 5, 2011
P=N/A, N=28, Completed, Sponsor: Göteborg University
Recruiting --> Completed Recruiting --> Completed
- cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial termination, Surgery: Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer (clinicaltrials.gov) - Oct 5, 2011
P1/2, N=20, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Completed Recruiting --> Terminated; Poor recruitment
- | cisplatin / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy: A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer (clinicaltrials.gov) - Oct 5, 2011
P1/2, N=30, Active, not recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Terminated; Poor recruitment Recruiting --> Active, not recruiting
- pegylated liposomal doxorubicin / Generic mfg.
Trial completion: Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer (clinicaltrials.gov) - Oct 5, 2011
P3, N=34, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Preclinical, Trial termination: Protocols for Improved in Vitro Fertilization (IVF) Outcomes (clinicaltrials.gov) - Oct 4, 2011
P4, N=2, Terminated, Sponsor: University of California, San Francisco
2 subjects were enrolled. There was NO enrollment after November 2007.
- ||||| seribantumab (MM-121) / Elevation Oncology
New P2 trial, Combination therapy, Metastases: A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers (clinicaltrials.gov) - Oct 4, 2011
P2, N=210, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
- azithromycin / Generic mfg.
Clinical: Incure: Incubation Time and Test of Cure of Chlamydia Trachomatis (clinicaltrials.gov) - Oct 3, 2011
P=N/A, N=52, Completed, Sponsor: Maastricht University Medical Center
- Enrollment change: MASH: Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study (clinicaltrials.gov) - Oct 2, 2011
P4, N=12, Completed, Sponsor: University of Pittsburgh
There was NO enrollment after November 2007. N=35 --> 12